Company Details

Anatara Lifesciences Ltd (ASX: ANR)

ASX Listed
Clinical Development, Commercialisation
Healthcare / Life Sciences / Medical Devices, Biotech
General Investor Profiling, Raising Capital

Company Information

  • Executive Summary

    Executive Summary

    Anatara Lifesciences (ASX: ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products.

    Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

    Register Interest

    Problem and Solution Overview

    Gastrointestinal Reprogramming Product (GaRP)

    Introducing GaRP, a microbiome-targeted dietary supplement

    Anatara’s GaRP product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders.

    Our lead product is being positioned as an adjunct to existing therapies, and it will not be replacing current prescription medications. Over the last 20 years, the use of dietary supplements as adjuncts to prescription drugs has increased significantly.

    GI disorders affect a significant proportion of the population at some stage of their life. Approximately 50% of IBS and 30-50% of IBD patients seek additional relief of their symptoms through the use of adjunct therapies – this approach is generally precipitated by the high failure rates of current prescription therapies. Increased education and more detailed evaluation of dietary supplements and has led to health-care providers working with patients to develop individualised programs which include dietary supplements in the symptom management for GI disorders.

    Developing a dietary supplement provides several regulatory and commercial advantages as it is less expensive than prescription medicines and has a less risky pathway to market, thereby accelerating market entry. Both the public and health care professionals alike understand the term ‘dietary supplement’ and with the right partner, marketing can be aimed at both the public and professionals. Unlike pharmaceuticals, demonstrating superiority to other products is not necessary. Marketing, sales, and medical affairs activities encourage health care professionals to recommend products to their patients. Therefore, finding and selecting the best marketing partner is critical to the success of a product such as GaRP and consequently this has and will continue to be a major focus for Anatara.

    The design of GaRP has been enabled by leveraging published research in conjunction with the extensive body of knowledge generated in-house at Anatara. Bromelain is one of the main components of GaRP and therefore forms the basis of its acceptability as an effective dietary supplement.

    Anatara has been actively working on the development of the GaRP product and has completed the dose selection of each formulation component. The Company has recently generated in vitro data to support the effectiveness of GaRP in: • Removing bacteria with pro-inflammatory properties;

    • Reducing inflammation by reducing the release of pro-inflammatory cytokines;
    • Regenerating the integrity of the gastrointestinal tract; and
    • Stimulating mucosal healing. Further information on the proof of concept results can be found here

    Anatara will commence planning for a human clinical study for IBS with patient recruitment anticipated to start in the second half of 2019.

    In parallel Anatara will move GaRP into the final stage of pre-clinical development for IBD with mouse pre-clinical studies expected to be completed by end of July 2019.

    Further information on our human development plans will be provided in the near future.

  • Company Highlights

    Company Highlights

    • Negotiated an exclusive global licensing agreement for the worldwide development, distribution and marketing of our first animal product, Detach, with Zoetis Inc – leading global animal health company
    • Detach received regulatory approval from Australian Pesticides and Veterinary Medicines Authority (APVMA) for use in piglets
    • Growth in Anatara’s skill set, with key appointments with significant human health experience, including Sue MacLeman and Dr Jane Ryan, to the Board of Directors, and Steven Lydeamore as CEO
    • Human development program well underway – developing scientifically innovative and commercially attractive products for gastrointestinal health in areas of critical need
    • First product candidate – Gastrointestinal ReProgramming (GaRP) dietary supplement is aimed at restoring and maintaining gut health – proof of concept studies are well advanced
    • Formation of our Product Development Advisory Board with world-leading scientists and clinicians in gastrointestinal health
    • Company well funded with $7.1m in bank
    • Sufficiently funded to execute on the development and partnering of our GaRP dietary supplement
  • Board & Management

    Board & Management

    Steve  Lydeamore

    Steve Lydeamore

    CEO
    25+ years international pharmaceutical experience in Australia, USA and Canada, Lead roles in global business development, manufacturing and finance, including the commercialisation of numerous consumer drug products, MBA, CPA, GAICD
    Dr Tracey  Brown

    Dr Tracey Brown

    CDO
    20+ years experience in biotechnology and pharmaceutical product development – from conception to registration and reimbursement, Lead roles in research institutions in USA & Australia, Assoc Prof Monash University – research commercialisation
    Dr Michael  West

    Dr Michael West

    COO
    25+ years in the pharmaceutical industry internationally Medicinal chemist with lead roles in drug discovery, drug development and manufacture, Qualified Patent and Trademark Attorney
    Sue  MacLeman

    Sue MacLeman

    Chair
    30+ years pharmaceutical, biotechnology and medical technology experience in corporate, medical, commercial and business development, Has served as CEO and Board member of several ASX and NASDAQ listed companies, MBA, LLM, ATSE Fellow, AICD
    Dr Tracie  Ramsdale

    Dr Tracie Ramsdale

    Director
    30+ years drug discovery, design and development experience, Multiple corporate financing transactions and product licensing deals with global pharmaceutical and manufacturing companies, MPharm, PhD, ATSE Fellow, AICD
    Dr Jane  Ryan

    Dr Jane Ryan

    Director
    30+ years international experience in the pharmaceutical and biotechnology industries, VP Product Development & Strategic Marketing and Director of Business Development at Biota Holdings Ltd (Relenza), Led multiple successful fundraising campaigns and licensing initiatives including...

    30+ years international experience in the pharmaceutical and biotechnology industries, VP Product Development & Strategic Marketing and Director of Business Development at Biota Holdings Ltd (Relenza), Led multiple successful fundraising campaigns and licensing initiatives including the awarding of a $230m US Gov contract

    Dr David  Brookes

    Dr David Brookes

    Director
    30+ years experience in medicine and biotechnology sector, Medical practitioner M.B.B.S, R.A.C.O.G. F.A.C.R.R.M., Numerous board positions in ASX listed biotechnology companies including RHS Ltd & Atcor Medical Holdings

    30+ years experience in medicine and biotechnology sector, Medical practitioner M.B.B.S, R.A.C.O.G. F.A.C.R.R.M., Numerous board positions in ASX listed biotechnology companies including RHS Ltd & Atcor Medical Holdings

  • Contact Details

    Contact Details